CAR-T cell therapy is a personalized cellular immunotherapy in which a patient’s T cells are genetically engineered to recognize a specific target on cancer cells. The strongest established evidence is currently in selected hematologic malignancies, including certain leukemias, lymphomas and multiple myeloma. Eligibility depends on the diagnosis, target antigen, previous treatment and the patient’s clinical condition. CAR-T therapy for solid tumors remains an active area of clinical research.